Medinteract’s co-founder, Dr. John Dougherty and Dr. Alan Solomon from the University of Tennessee Medical Center, discuss the exciting research collaboration with Eli Lilly and Co. and the newly FDA-approved Amyvid which is used in the early diagnosis of mild cognitive impairment (MCI) and early Alzheimer’s disease.
Posts Tagged ‘ALZselftest’
- April 20th, 2010
A few days ago we received a very nice testimonial on our Facebook page and it made me realize that what we offer is truly two-fold. Here is the message we received:
I took the self test today, and the results were excellent in all areas. With a family history of Alzheimer’s, having access to a quick, easy, affordable tool to catch problems early, gives me great peace of mind. Now I’ll chalk up my memory problems to overwork, rather than to early ALZ.
We offer the ALZselftest as a way to help people discover early warning signs of Alzheimer’s and get diagnosed early, when treatment options are most effective. But on the other side are the millions of baby boomers who have begun to worry that their memory lapses are something far more serious than mere absent-mindedness or paying insufficient attention. For these folks, like our commenter above, the ALZselftest offers a quick, highly accurate way to find “peace of mind”. The less time you spend fretting about the occasional lost set of keys, the more clear your mind will be, and the better you’ll feel each day.
Do not fear the outcome! Knowledge is power, and for the first time you are empowered with the tools to screen your mind and learn crucial information about your cognitive function. Besides, think how relieved you will be when you find out that you forget the same things the rest of us do, and are suffering no serious deficits within any of your cognitive domains! Don’t delay, screen your brain today.
- March 29th, 2010
Here is the latest list of sites featuring articles on the Computerized Self Test, or, the ALZselftest.com:
From Science Daily
New Article on Computerized Self Test from Medscape
- March 3rd, 2010
KNOXVILLE – Early detection is key to more effective treatment for Alzheimer’s disease and other forms of cognitive impairment, and new research shows that a test developed by researchers at the University of Tennessee, Knoxville, is more than 95 percent effective in detecting cognitive abnormalities associated with these diseases.
The test, called CST — for computerized self test – was designed to be both effective and relatively simple for medical professionals to administer and for patients to take.
Rex Cannon, an assistant professor of psychology at UT Knoxville, and Dr. John Dougherty, an associate professor in the UT Graduate School of Medicine, worked with a team of researchers to develop CST. The impetus for the test came from data showing that 60 percent of Alzheimer’s cases are not diagnosed in the primary care setting, and that those delays lead to missed treatment opportunities.
“Early detection is at the forefront of the clinical effort in Alzheimer’s research, and application of instruments like CST in the primary care setting is of extreme importance,” said Cannon.
The CST is a brief, interactive online test that works to asses various impairments in functional cognitive domains – in essence, it’s a fitness test of sorts for the basic functions of thinking and processing information that are affected by Alzheimers and milder forms of cognitive impairment.
Cannon and Dougherty’s research, published in the April issue of the Journal of Alzheimer’s Disease, showed that the CST was substantially more effective and more accurate in detecting the presence of Alzheimer and other forms of cognitive impairment in patients than other existing tests. The CST had a 96 percent accuracy rate compared to 71 percent and 69 percent for the tests that are currently in use.
Part of the goal in developing the test, according to Cannon, was to ensure that the test is useful in the primary care setting, where physicians may not have detailed training in recognizing cognitive impairments, but where an early diagnosis may do the most good for patients.
“Computerized testing is a developing and exciting area for research,” said Cannon, who noted that the test can provide an objective way to determine what diseases may affect the patient and provide information to begin treatments that can blunt the effects of Alzheimer’s.
Cannon and Dougherty, who are also affiliated with the Cole Neuroscience Institute at the UT Medical Center, collaborated with Medical Interactive Education in developing the CST over the past two years.
The journal article is titled “The Computerized Self Test (CST): An Interactive, Internet Accessible Cognitive Screening Test For Dementia,” Journal of Alzheimer’s Disease, 20 (1) and The test can be found at www.alzselftest.com.
The caregivers of my patients frequently ask me about the safety of their loved ones getting behind the wheel after receiving a diagnosis of Alzheimer’s Disease (AD). This is a sensitive topic for patients, but a very important one in terms of both safety and liability, as I will discuss here.
First, my own research has recently revealed that driving in moderate and late stage AD is a much larger problem than we first feared, and this is not attributable merely to aging. In fact, we have seen that 16 year old males have a higher incidence of accidents than healthy non-demented individuals over the age of 75. However, in mild cognitive impairment (MCI) and the early stages of AD, we do not see increased accident rates. But as early AD progresses into moderate AD accident rates rise sharply. Read More